Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
34 hedge funds and large institutions have $5.76M invested in Bellicum Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
55% more funds holding
Funds holding: 22 → 34 (+12)
14% less capital invested
Capital invested by funds: $6.7M → $5.76M (-$940K)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.11M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$673K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$418K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$281K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$224K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$691K |
| 2 |
Renaissance Technologies
New York
|
-$561K |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$362K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$190K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$108K |
BLCM Hedge Fund Activity: Q4 2020 in Review
34 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2020, worth a combined $5.76M — down 14% from $6.7M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new BLCM positions and 5 closed out — a net gain of 12 holders — while 3 added to existing stakes and 7 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.11M. The largest seller was Frazier Management, exiting entirely with an estimated $691K sold.
- 34 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2020, up from 22 in Q3 2020.
- Funds reported $5.76M of Bellicum Pharmaceuticals, Inc. stock for Q4 2020, down 14% quarter-over-quarter.
- 17 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2020 and 5 closed out, a net change of +12 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2020 was Ikarian Capital, an estimated $2.11M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2020 was Frazier Management, an estimated $691K sold.
Based on aggregated 13F filings for Q4 2020.